| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/08/2009 | EP2043649A2 Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments |
| 04/08/2009 | EP2043648A1 Use of flibanserin for the treatment of sexual disorders in females |
| 04/08/2009 | EP2043647A2 Controlled release formulations and associated methods |
| 04/08/2009 | EP2043646A2 Glucocorticoid receptor modulator and methods of use |
| 04/08/2009 | EP2043645A2 Compounds and compositions for treatment of cancer |
| 04/08/2009 | EP2043644A1 Nf- b inhibitor |
| 04/08/2009 | EP2043643A2 Use of derivatives of imidazo[1, 2-a]pyridine-2-carboxamides in therapeutics |
| 04/08/2009 | EP2043642A2 Compositions and methods relating to solenopsins and their uses in treating neurological disorders and enhancing physical performance |
| 04/08/2009 | EP2043641A2 Combinations of monoamine reuptake inhibitors and potassium channel activators |
| 04/08/2009 | EP2043640A2 Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients |
| 04/08/2009 | EP2043639A2 Processes for preparing polymorphic forms of solifenacin succinate |
| 04/08/2009 | EP2043638A2 Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders |
| 04/08/2009 | EP2043637A2 Methods and medicaments for administration of ibuprofen |
| 04/08/2009 | EP2043636A2 (combi) compositions for the treatment of mucormycosis comprising iron chelator and antifungal agent |
| 04/08/2009 | EP2043634A2 Substituted pyrazoles as ghrelin receptor antagonists |
| 04/08/2009 | EP2043633A2 Thiadiazolidinone derivatives |
| 04/08/2009 | EP2043632A2 New indications for direct thrombin inhibitors |
| 04/08/2009 | EP2043631A2 New indications for direct thrombin inhibitors in the cardiovascular field |
| 04/08/2009 | EP2043630A2 6, 9-disubstituted purine derivatives and their use for treating skin |
| 04/08/2009 | EP2043629A1 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases |
| 04/08/2009 | EP2043628A2 Ultraviolet absorbing ophthalmic compositions |
| 04/08/2009 | EP2043627A2 Iron(ii)-containing treatments for hyperphosphatemia |
| 04/08/2009 | EP2043626A1 Composition comprising a retinoid and benzoyl peroxide |
| 04/08/2009 | EP2043625A1 Nfkappab inhibitors to treat pain locally |
| 04/08/2009 | EP2043624A2 Combination of modafinil and an antagonist or inverse agonist of the h3 receptor |
| 04/08/2009 | EP2043623A2 Nanoparticulate formulations of modafinil |
| 04/08/2009 | EP2043622A2 Beta acid based protein kinase modulation cancer treatment |
| 04/08/2009 | EP2043621A2 Hexahydro-isoalpha acid based protein kinase modulation cancer treatment |
| 04/08/2009 | EP2043620A2 Compositions and methods for treating parasitic infections |
| 04/08/2009 | EP2043619A2 Chewable tablet containing phenylephrine |
| 04/08/2009 | EP2043618A1 Pharmaceutical formulation comprising donepezil |
| 04/08/2009 | EP2043615A2 Pharmaceutical compositions comprising levetiracetam |
| 04/08/2009 | EP2043614A2 Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient |
| 04/08/2009 | EP2043612A1 A stable olanzapine formulation with antioxidants |
| 04/08/2009 | EP2043608A1 Powders for reconstitution |
| 04/08/2009 | EP2043607A2 Process for the preparation of micronized valsartan |
| 04/08/2009 | EP2043604A2 Topical compositions |
| 04/08/2009 | EP2043603A2 Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
| 04/08/2009 | EP2043598A1 Extended release perforated tablet |
| 04/08/2009 | EP2043590A1 Barrier film-forming germicidal compostition for controlling mastitis |
| 04/08/2009 | EP1970061A4 Medicinal agent for treating viral infections |
| 04/08/2009 | EP1940366B1 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| 04/08/2009 | EP1931671B1 Alkyl 4- [4- (5-oxo-2, 3, 5, 11a-tetrahyd0-5h-pyrr0l0 [2, 1-c][1, 4]benzodiazepine-8-yloxy) -butyrylamino]-1h-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease |
| 04/08/2009 | EP1833782B1 Cycloalkylamine derivatives |
| 04/08/2009 | EP1831198B1 Pyridine carboxamide derivatives for use as anticancer agents |
| 04/08/2009 | EP1831193B1 Imidazole derivatives |
| 04/08/2009 | EP1828110B1 Process for the preparation of tamsulosin and intermediates thereof |
| 04/08/2009 | EP1814846B1 11beta-hsd1 inhibitors |
| 04/08/2009 | EP1753803B1 Polypeptides with the capacity to entrap drugs and release them in a controlled way |
| 04/08/2009 | EP1718667A4 Heterocyclic self-immolative linkers and conjugates |
| 04/08/2009 | EP1706114A4 Chemical inhibitors of soluble adenylyl cyclase (sac) |
| 04/08/2009 | EP1682496B1 Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| 04/08/2009 | EP1682122B9 Combinations of valsartan, amiloride or triamterine, and a diuretic |
| 04/08/2009 | EP1673065B1 Microemulsions of retinoids, and pharmaceutical compositions containing them |
| 04/08/2009 | EP1670470B1 Pyridine derivatives and use thereof as urotensin ii antagonists |
| 04/08/2009 | EP1634590A4 Coronavirus inactivating agent |
| 04/08/2009 | EP1630160B1 The isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as the effective constituents |
| 04/08/2009 | EP1625135B1 Fondaparinux sodium composition of high purity |
| 04/08/2009 | EP1594499B1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer |
| 04/08/2009 | EP1565475B1 Diazinopyrimidines and their use as protein kinase inhibitors |
| 04/08/2009 | EP1551830B1 Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibators |
| 04/08/2009 | EP1545710B1 Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer |
| 04/08/2009 | EP1513811B1 Non-peptidic brs-3 agonists |
| 04/08/2009 | EP1496760B1 Acidic compositions comprising protein and fiber and processes of their preparation |
| 04/08/2009 | EP1461340B1 Trioxane derivatives as antimalaria or anticancer compounds |
| 04/08/2009 | EP1461015B1 Compositions containing both sedative and non-sedative antihistamines |
| 04/08/2009 | EP1461013A4 Method of producing a nicotine composition |
| 04/08/2009 | EP1448566B3 Chemokine receptor antagonists and methods of use thereof |
| 04/08/2009 | EP1442026B1 Triazole derivatives as cyclooxygenase (cox) inhibitors |
| 04/08/2009 | EP1441708B1 Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| 04/08/2009 | EP1430023B1 Substituied urea retinoid agonists ii |
| 04/08/2009 | EP1415986B1 Spiro isobenzofuranes as neuropeptide y receptor antagonists |
| 04/08/2009 | EP1409076A4 Method and apparatus for treating tumors using low strength electric fields |
| 04/08/2009 | EP1389209B1 Folate mimetics and folate-receptor binding conjugates thereof |
| 04/08/2009 | EP1265868B1 Preparation of DIBENZO[B,F]AZEPINE INTERMEDIATES |
| 04/08/2009 | EP1218004B1 5-methyl indirubin for use in the treatment of human solid tumors |
| 04/08/2009 | EP1212299B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |
| 04/08/2009 | EP1179345B1 Inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4-dihydropyridine derivatives |
| 04/08/2009 | EP1059925B1 Ep2-receptor agonists as neuroprotective agents for the eye |
| 04/08/2009 | EP0996418B2 Dermatological compositions |
| 04/08/2009 | EP0961612B1 Protein stabilized pharmacologically active agents and their use |
| 04/08/2009 | EP0931063B3 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect |
| 04/08/2009 | EP0861266B3 Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them |
| 04/08/2009 | EP0644767B3 Veterinary rehydration product |
| 04/08/2009 | EP0566709B3 Composition comprising a tramadol compound and acetaminophen, and its use |
| 04/08/2009 | CN201216753Y Dressings emplastrum for relieving pain of tumour |
| 04/08/2009 | CN101405291A 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated Kv1.3 potassium channel |
| 04/08/2009 | CN101405290A Polymorphs of Eszopiclone malate |
| 04/08/2009 | CN101405289A Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof |
| 04/08/2009 | CN101405288A Imidazopyridin-2-one derivatives as inhibitors of endothelial lipase |
| 04/08/2009 | CN101405287A Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/08/2009 | CN101405286A Hydantoin derivatives for the treatment of inflammatory disorders |
| 04/08/2009 | CN101405285A Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and P53 |
| 04/08/2009 | CN101405283A HIV inhibiting 5-amido substituted pyrimidines |
| 04/08/2009 | CN101405281A Inhibitors of the interaction between MDM2 and P53 |
| 04/08/2009 | CN101405277A Dicarbonylic compounds with antibacterial activity |
| 04/08/2009 | CN101405276A Compositions and methods for the inhibition of phospholipase A2 |
| 04/08/2009 | CN101405275A Triazolone derivative |
| 04/08/2009 | CN101405272A Novel solid forms of (4R)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4H-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid |
| 04/08/2009 | CN101405271A Rimonabant monohydrate, process for the preparation thereof and pharmaceutical compositions containing same |